Evolus, Inc.

Name: Evolus, Inc. standardized financial statements, quarterly
Creator: Listed

EOLSNasdaqCIK 1570562HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$84.1m, Q2 FY2026

Operating income−$4.5m, Q2 FY2026

Net income−$8.1m, Q2 FY2026

Evolus, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	50.0	61.0	59.3	66.9	61.1	78.9	68.5	69.4	69.0	90.3	73.1	84.1
Cost of revenue	$m	15.4	22.2	18.8	19.8	19.0	26.3	21.9	24.1	23.1	31.0	24.2	26.9
Gross profit	$m	not reported	not reported	40.5	47.1	42.1	52.6	46.7	45.3	45.8	59.3	48.9	57.2
Research and development	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Selling, general and administrative	$m	43.3	43.1	45.1	50.2	52.5	50.2	56.6	56.7	52.8	54.7	52.0	57.1
Operating income	$m	(13.4)	(8.6)	(8.9)	(7.7)	(15.5)	(2.3)	(15.2)	(10.2)	(11.5)	4.2	(6.8)	(4.5)
Interest expense	$m	3.8	4.1	4.7	4.7	4.8	4.6	4.4	7.2	4.1	4.0	4.0	4.2
Income tax	$m	0.0	0.1	0.0	0.0	0.1	0.4	0.1	0.1	0.2	0.4	0.3	(0.2)
Net income	$m	(16.9)	(11.8)	(13.1)	(11.4)	(19.2)	(6.8)	(18.9)	(17.1)	(15.7)	0.1	(10.7)	(8.1)
Diluted EPS	$ per share	(0.30)	not reported	(0.22)	(0.18)	(0.30)	not reported	(0.30)	(0.27)	(0.24)	not reported	(0.16)	(0.12)
Basic EPS	$ per share	(0.30)	not reported	(0.22)	(0.18)	(0.30)	not reported	(0.30)	(0.27)	(0.24)	not reported	(0.16)	(0.12)

Balance sheet

Cash and equivalents$45.2m, Q2 FY2026

Long-term debt$156.7m, Q2 FY2026

Shareholders' equity−$30.9m, Q2 FY2026

Evolus, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	38.7	62.8	97.0	93.7	85.0	87.0	67.9	61.7	43.5	53.8	49.8	45.2
Current assets	$m	92.0	112	150	158	150	151	132	145	135	143	139	168
Total assets	$m	168	189	226	234	230	233	213	229	219	226	221	248
Current liabilities	$m	48.5	48.3	46.8	54.1	60.8	63.0	56.2	63.8	66.7	75.3	68.0	98.7
Total liabilities	$m	187	210	208	214	224	227	220	247	248	249	249	279
Long-term debt	$m	95.1	120	121	121	121	122	122	145	146	146	156	157
Shareholders' equity	$m	(19.4)	(20.7)	18.4	19.3	5.9	5.5	(6.6)	(18.7)	(28.8)	(23.1)	(28.8)	(30.9)

Cash flow

Operating cash flow−$3.6m, Q2 FY2026

Capital expenditure$50.0k, Q2 FY2026

Evolus, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(0.9)	0.8	(10.6)	(6.5)	(5.7)	4.8	(15.6)	(24.8)	(14.7)	12.8	(10.0)	(3.6)
Capital expenditure	$m	0.0	0.2	0.3	0.5	0.3	0.4	0.3	0.7	1.0	1.5	0.4	0.1

Diluted shares (weighted)65.93m, Q2 FY2026

Evolus, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	56.2	56.5	56.9	57.0	58.8	62.7	63.1	63.7	64.5	64.7	65.2	65.9

Shares outstanding: 66.05m at Jul 31, 2026, from the cover of the 10-Q filed Aug 5, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. Listed shows no prices and gives no investment advice.